Introduction
============

Neuropathic pain is caused by lesions in the somatosensory pathway in the peripheral or central nervous system. A change in the activation of the pain matrix is thought to be one of the mechanisms responsible for the pathogenesis of neuropathic pain.^[@B1]^ The pain matrix consists of a network of brain structures that include areas such as the thalamus, anterior cingulate cortex, and somatosensory cortices, among other regions. Since most neuropathic pain patients do not respond sufficiently to medical treatment, non-medical approaches such as neuromodulation therapies have been developed. The main neuromodulation therapies currently being used for chronic neuropathic pain include motor cortex stimulation (MCS) and spinal cord stimulation (SCS).

MCS was first proposed for the treatment of central poststroke pain (CPSP).^[@B2],[@B3]^ Subsequently, several case series have reported on the efficacy of MCS for multiple types of pain including trigeminal neuropathic pain, phantom limb pain, and spinal cord injury (SCI) pain.^[@B4]--[@B11]^ Four randomized controlled trials with a crossover design have been published.^[@B12]--[@B15]^ SCS has now become the most widely used neuromodulation therapy due to the less invasiveness, low complication rate, and effectiveness.^[@B16],[@B17]^ Other reasons for the increased use of SCS instruments include improvements in the devices.^[@B18],[@B19]^ The efficacy of SCS for particular types of peripheral neuropathic pain has been demonstrated by randomized controlled trials examining failed back surgery syndrome (FBSS),^[@B20],[@B21]^ complex regional pain syndrome (CRPS) type I,^[@B22]^ painful diabetic neuropathy,^[@B23],[@B24]^ and angina pectoris.^[@B25]^

Although neuromodulation therapies are performed throughout the world to treat various chronic neuropathic pains, predictive factors for the long-term effects have yet to be established. While it has been documented that patients do express dramatic pain relief after undergoing neuromodulation therapy, it remains unclear as to the mechanism responsible for bringing about the dramatic pain relief. The aim of this study was to evaluate the rates of the long-term effects and the predictive factors associated with the long-term effects in both MCS and SCS, and the differences between the dramatic and moderate pain relief in both MCS and SCS.

Methods
=======

Patients and methods
--------------------

This study was a retrospective review of 50 consecutive patients who underwent surgical implantation of MCS or SCS electrodes for the treatment of chronic neuropathic pain by the Functional Neurosurgery Team of Nagoya University. Procedures were performed at either the Nagoya University Hospital or Nagoya Central Hospital in Japan from 1999 to 2016. All patients exhibited a poor response to medications before surgery. MCS was performed from 1999 to 2009. Since 2010, the eight-contact electrodes and an implantable pulse generator stimulating 16 contacts became available for clinical use in Japan. Then, we select SCS for patients who presented with lumbar, upper, or lower extremity pain. Only when the patient presented with facial pain, we select MCS. Patients found to have severe depression, psychiatric disorders, drug abuse, or who did not have a sufficient ability to communicate due to severe neurological deficits were excluded from the analysis. The study protocol was approved by the local ethics committees of the Nagoya University Hospital and Nagoya Central Hospital. All patients were informed about the procedure and provided written informed consent prior to the start of the study.

Patients who underwent MCS/SCS electrode implantation
-----------------------------------------------------

Fifteen patients underwent implantation of MCS electrodes. The mean age ± standard deviation was 56.1 ± 13.6 years. The preoperative mean duration of pain was 3.5 ± 2.3 years. Patients were classified according to the anatomical location of lesion as follows: central pain of brain (*n* = 9), central pain of spinal cord (*n* = 2), and peripheral neuropathic pain (*n* = 3). Causes of pain included CPSP (*n* = 9), SCI (*n* = 2), peripheral neuropathy (*n* = 3), and other causes (*n* = 1). Sites of pain were upper extremity (*n* = 3), lower extremity (*n* = 1), upper and lower extremities (*n* = 8), and face (*n* = 3). [Table 1](#T1){ref-type="table"} summarizes the clinical features and outcomes of the patients who underwent MCS.

Thirty-five patients underwent implantation of SCS electrodes. The mean age of the patients was 63.4 ± 12.2 years. The preoperative mean duration of pain was 4.4 ± 3.7 years. Patients were classified according to the anatomical location of lesion as follows: central pain of brain (*n* = 18), central pain of spinal cord (*n* = 4), and peripheral neuropathic pain (*n* = 13). Causes of pain were CPSP (*n* = 17), FBSS (*n* = 7), SCI (*n* = 4), peripheral neuropathy (*n* = 3), CRPS type I (*n* = 1), and other causes (*n* = 3). Sites of pain were upper extremity (*n* = 5), lower extremity (*n* = 9), upper and lower extremities (*n* = 13), lumbar (*n* = 3), lumbar and lower extremity (*n* = 4), and other (*n* = 1). [Table 2](#T2){ref-type="table"} summarizes the clinical features and outcomes of the patients who underwent SCS.

MCS electrode implantation procedures
-------------------------------------

A preoperative magnetic resonance image was taken after placement of fiducial markers. After using a preliminary target to calibrate the image-guided navigation system, a skin incision and one burr hole around the central sulcus were made under local anesthesia. A six-plate electrode array was inserted from the edge of the burr hole into the epidural space, with the locations of the precentral and postcentral gyri confirmed by the phase reversal of the N20 wave of the somatosensory evoked potential recorded by median nerve stimulation. A four-plate electrode array (3587A Resume II; Medtronic Inc., Minneapolis, MN, USA) was inserted into the pain site target on the precentral gyrus, with muscle contraction of the pain area through bipolar stimulation via the electrodes used to confirm the location.

SCS electrode implantation procedures
-------------------------------------

After each patient was placed in the prone position, the 18-gauge Tuohy needle was inserted into the midline epidural space under local anesthesia. Four-contact electrodes (Pisces Quad, Model 3487A; Medtronic Inc.) were inserted in the initial four subjects. Once the eight-contact electrodes and an implantable pulse generator became available for clinical use, we began inserting the eight-contact electrode (Octad Lead Standard, Model 3777, Vectris SureScan MRI Compact, Model 977A2; Medtronic Inc.). For dual-lead SCS, two electrodes were placed in parallel. In two subjects, we employed 4 four-contact electrodes. When insertion of two electrodes was technically difficult, only one electrode was inserted. The electrodes were manipulated using radiographic guidance, with the stimulation-induced paresthesia covering the entire region affected by the pain.

Test stimulation and implantation of the implantable pulse generator
--------------------------------------------------------------------

A test stimulation (= trial) was performed approximately 7 days after the insertion of the MCS or SCS electrodes in order to assess the efficacy and adverse effects. When a reduction of \> 50% was achieved in the VAS, this was defined as a "trial success". If deemed successful, the electrode was then connected to an implantable pulse generator (IPG) under general anesthesia. The MCS electrode was connected to an IPG (Itrel III; Medtronic Inc.). The SCS electrode was connected to an IPG (Synergy, PrimeAdvanced, PrimeAdvanced SureScan MRI or RestoreSensor SureScanMRI; Medtronic Inc.). If the trial was not successful, the electrode and percutaneous extension were removed from the patient.

Assessment
----------

The degree of pain was assessed using the Visual Analog Scale (VAS). Assessments of pain were performed at the time when it's most painful during 1 day, because the pain fluctuated during 1 day. The preoperative VAS score was used as the baseline. Postoperative outcomes were assessed at 1, 6, and 12 months after the surgery, and at the time of the last follow-up. Percentages of pain relief (PPR) from the preoperative VAS were calculated at 1, 6, and 12 months after the surgery, and at the time of the last follow-up \[PPR (%) = (preoperative VAS − postoperative VAS)/preoperative VAS × 100\]. MCS and SCS outcomes were classified into two sub-categories according to the PPR, with ≥ 70% indicating an excellent outcome and 30--69% indicating a good outcome. We defined a successful "long-term effect" as a patient who achieved a PPR ≥ 30% and who had continuous pain relief over 12 months. Failure was defined as a PPR \< 30% as compared to the baseline. Patients were additionally separated into three groups according to their trial and long-term outcomes as follows: (1) trial success with implantation of the IPG and an observed long-term effect (long-term effect group), (2) trial success with implantation of the IPG, but without any long-term effect (no long-term effect group), and (3) the trial was not a success and the IPG was not implanted (no trial success group).

Statistics
----------

The three trial groups were analyzed by an ANOVA using age, duration of pain, and preoperative VAS scores to compare the preoperative patient conditions for the MCS and SCS. The factors used for the Fisher's exact test included sex, location of lesion, sensory disturbance, motor weakness, site of pain, and laterality of pain. The Fisher's exact test was also used to determine the relationship between the long-term effect of MCS/SCS and the location of lesion. Wilcoxon rank sum test using the postoperative VAS scores at 1, 6, and 12 months after the surgery, and at the time of the last follow-up was performed in order to compare the difference between the long-term effect and the no long-term effect groups of MCS and SCS. The Wilcoxon rank sum test was also performed to compare the difference between the excellent and good groups of MCS and SCS using age, duration of pain, and the preoperative and postoperative VAS scores at 1, 6, and 12 months after the surgery, and at the time of the last follow-up. Fisher's exact test was also used to examine the differences in the sex, location of lesion, sensory disturbance, motor weakness, site of pain, and laterality of pain. Probability values of less than 0.05 were considered statistically significant. To investigate the long-term effect group of SCS, we used the PPR score at 1 month after the surgery. The point with the best sum of sensitivity and specificity for the Youden Index in the receiver operating characteristic (ROC) curve was defined as the cut-off value. We used the "exactRankTests" and "pROC" packages for the Wilcoxon rank sum test analysis and ROC analysis, respectively, which is included in the statistical software R version 3.1.3.

Results
=======

Outcomes of MCS/SCS
-------------------

[Table 3](#T3){ref-type="table"} shows the outcomes of the trial and the long-term effects of MCS and SCS. In the 15 patients implanted with MCS electrodes, 11 (73.3%) had a trial success. Eight of the 11 patients who were implanted with the MCS and IPG system achieved successful long-term effects. During the mean follow-up period of 105.4 ± 41.9 months, eight out of 15 (53.3%) patients achieved successful long-term effects overall. All eight patients achieving long-term effects continued the effect for more than 2 years. In the 35 patients implanted with the SCS electrodes, 27 (77.1%) had a trial success. Twenty of the 27 patients who were implanted with the SCS and IPG system achieved successful long-term effects. During the mean follow-up period of 44.8 ± 26.3 months, 20 out of 35 (57.1%) patients achieved successful long-term effects overall. Fourteen out of 20 patients achieving long-term effects continued the effect for more than 2 years. There were no MCS or SCS patients who required removal of the system due to infection.

Relationship between the location of lesion and long-term effect of MCS/SCS
---------------------------------------------------------------------------

The respective long-term effect rates for the MCS and SCS in accordance with the location of lesion were 44.4% (4/9) and 44.4% (8/18) for the brain, 100% (2/2) and 75% (3/4) for the spine, and 66.7% (2/3) and 69.2% (9/13) for the peripheral nerves ([Table 3](#T3){ref-type="table"}). There was no statistical relationship observed between the long-term effect of MCS/SCS and the location of lesion. The respective long-term effect rates for the MCS and SCS in accordance with the cause of pain were 33.3% (3/9) and 41.2% (7/17) for CPSP, 100% (2/2) and 75% (3/4) for SCI, 71.4% (5/7) for FBSS in SCS, and 100% (1/1) for CRPS type I in SCS ([Table 3](#T3){ref-type="table"}).

Predictive factors of the long-term effect of MCS/SCS
-----------------------------------------------------

[Tables 4](#T4){ref-type="table"} and [5](#T5){ref-type="table"} show the comparisons of the characteristics for MCS and SCS among the long-term effect, no long-term effect, and no trial success groups, respectively. No statistical differences were observed for the age, sex, duration of pain, location of lesion, sensory disturbance, motor weakness, site of pain, laterality of pain, and preoperative VAS scores among the three groups for both MCS and SCS. Interestingly, there were statistical differences in the VAS scores at 1 and 6 months after the surgery between the long-term effect group and the no long-term effect group for both MCS and SCS (*P* \< 0.05). [Figure 1](#F1){ref-type="fig"} shows the scatter graph for the PPR at 1 month after SCS implantation versus the length of the continuing SCS effect. The cut-off value of the PPR at 1 month after SCS implantation versus the length of the continuing SCS effect was 50%, with a sensitivity of 100% and specificity of 75%.

Comparison between excellent and good groups of MCS/SCS
-------------------------------------------------------

The rates of excellent outcome at the time of the last follow-up were 37.5% (3/8) in MCS and 45.0% (9/20) in SCS patients. There were no statistical differences for the preoperative characteristics between the excellent and good groups in both the MCS and SCS patients. [Figure 2](#F2){ref-type="fig"} shows the changes in the VAS scores of the excellent and good groups at 1 month after the surgery in MCS and SCS patients (a: MCS, b: SCS). There were several common findings between the MCS and SCS groups. The VAS scores of the excellent groups at 1 month after the surgery remained low from 1 month after the surgery until the time of the last follow-up. And, no patients with excellent groups at 1 month after surgery in both MCS and SCS, were removed the implantation system during follow up periods. In contrast, the VAS scores of the good groups at 1 month after the surgery exhibited a significant increase at 6 months after surgery compared to that seen at 1 month. In patients with good groups at 1 month after surgery, the implantation systems were removed in the 50.0% (3/6) in MCS and 58.3% (7/12) in SCS patients.

Discussion
==========

A previous review of the efficacy of MCS has reported that 57.6% of the examined patients overall had more than 40--50% pain relief.^[@B5]^ There have been several reports of the long-term effects of MCS with more than 3.5 years of follow-up.^[@B14],[@B26]--[@B28]^ Im et al. examined 21 patients with neuropathic pain who underwent MCS, and reported that the trial success rate was 76.2%, with long-term effects achieved in 52.4% during 53 ± 39 months of follow-up.^[@B26]^ These results are compatible with our current findings. Predictive factors associated with long-term effects of MCS are still unclear. Several previous studies have reported that preoperative characteristics of patients such as the age, sex, and duration of pain, among others, were not related to the long-term outcomes.^[@B14],[@B26]--[@B28]^ However, the level of pain relief at 1 month after MCS system implantation was reported to be a strong predictor of long-term relief.^[@B27]^ This result indicates that in the no long-term effect group, the initial pain relief might reflect the placebo effects. Thus, in order to achieve a long-term effect, this suggests that it is necessary to separate out these types of patients during the trial period. Rasche et al. investigated the use of MCS in 17 patients with chronic neuropathic pain.^[@B14]^ Note is the fact that there were no patients who exhibited vanishing effects during the follow-up. The test stimulation in this series was double-blind. In other words, real or placebo stimulations were performed after blinding of the patients and physicians, with all of the stimulation parameters controlled and programmed by an independent physician. Double-blinded stimulations are considered to be able to discriminate patients who may have placebo effects.

FBSS and CRPS type I have been suggested to be pain types that can be treated by SCS.^[@B29],[@B30]^ Percentages found for long-term effects in patients who have been subjected to more than 12 months of FBSS and CRPS type I were reported to be 60--70% and 63--72%, respectively.^[@B17],[@B31],[@B32]^ In our current series, the total rate for the long-term effect of SCS was 57.1%, with this rate affected by the proportion of the number of FBSS and CRPS type I in the patient groups. In our study, 23% of the total patients were FBSS and CRPS type I, while 63% had central neuropathic pain. Although the percentage for the long-term effects of SCS for peripheral origin pain was 69.2%, which was higher than for the brain origin pain (44.4%), there was no statistical difference between the two locations. The reason for this result is likely that SCS for CPSP had a comparatively high rate of long-term effects in our series. Although SCS has not been recommended for the treatment of central neuropathic pain,^[@B29],[@B30]^ it has been recently reported that some CPSP patients have been successfully treated by SCS.^[@B33],[@B34]^

Relationships of site of pain and efficacy of MCS were reported that upper extremity or face pain were easy to treat because of more easily localizing the epidural electrode array on the representation of the pain sites in the motor cortex.^[@B14]^ SCS was more efficacy for lower extremity or lumbar pain.^[@B17],[@B31]^ In our study, rates of long-term effects were 100% (3/3) of facial pain and 66.7% (2/3) of upper extremity pain in MCS, and 66.7% (6/9) of lower extremity pain and 75% (3/4) of both lower extremity and lumbar pain in SCS. However, there were no statistical difference between site of pain and efficacy of MCS/SCS. The reasons for this result were small number of MCS for lower extremity pain (1) and SCS for upper extremity (5), and SCS was not indicated facial pain.

Although several predictive factors associated with long-term effects of SCS have been reported, this remains controversial.^[@B17],[@B35]--[@B39]^ Psychological factors are commonly known to influence the effect of SCS.^[@B40]^ Systemic reviews have suggested that psychological factors such as somatization, depression, and anxiety are predictive factors of the poor performance of SCS.^[@B36],[@B37]^ Although we did not perform meticulous preoperative evaluations of the psychological conditions or double-blinded test stimulations in our series, we did find that values of the PPR at 1 month after the surgery might be a useful postoperative predictor of the long-term effect. The cut-off value for achieving the long-term effect of SCS was shown to be 50% of the PPR at 1 month after the surgery. Moreover, a sensitivity of 100% indicates that all patients will achieve long-term effects when the PPR at 1 month after surgery is higher than 50%. A specificity of 75% indicates that 75% of patients will not achieve the long-term effects when the PPR at 1 month after surgery is less than 50%.

There were similar finding for both the MCS and SCS, such as excellent groups at 1 month after the surgery remained the effect until the time of the last follow-up, and good groups at 1 month after the surgery exhibited a significant decrease in the effects at 6 months after surgery. We speculated that the similar features observed for MCS and SCS might imply a common underlying mechanism for pain relief. Neuroimaging studies have shown a significant correlation between the analgesic effect of MCS and the regional cerebral blood flow (rCBF) changes in various regions including the anterior cingulate gyrus, orbitofrontal cortex, thalamus, anterior insula, and brain stem.^[@B41]--[@B45]^ SCS also induces changes of activity in the anterior cingulate cortex and thalamus, which can be identified by increases and decreases in the rCBF.^[@B46]^ Previous neuroimaging studies have indicated that SCS induced modulations in the somatosensory and emotional areas of the brain.^[@B47]--[@B50]^ Therefore, the common modulations of the pain matrix induced by electrical stimulation may be one reason for the similar features observed for MCS and SCS.

Conclusion
==========

For non-selected patients with chronic neuropathic pain who did not undergo the double-blind test stimulation method, rates of the long-term effect of MCS and SCS were approximately 50% during the more than 8.5 and 3.5 years of follow-up, respectively. Although it remains unclear as to the preoperative predictive factors for the long-term effects, the VAS at 1 month after surgery may be a postoperative predictor of the long-term effects for both MCS and SCS. The cut-off value for achieving the long-term effect of SCS was shown to be 50% of the PPR at 1 month after the surgery. In order to increase the rates of the long-term effect for both MCS and SCS, it is necessary to select appropriate patients prior to the surgery and exclude those patients who demonstrate placebo effects during the trial period. Similar features were detected, such as excellent groups at 1 month after the surgery remained the effect until the time of the last follow-up in both MCS and SCS. This may reflect a common mechanism for pain relief. The limitations of our studies were the retrospective design and the small sample size. Prospective controlled studies with large sample sizes will need to be undertaken in order to provide further evidence.

**Conflicts of Interest Disclosure**

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (e.g., honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) or non-financial interest (e.g., personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.

**Informed Consent**

Informed consent was obtained from all individual participants included in the study.

![Cut-off value of the percentage of pain relief at 1 month after SCS. Scatter graph shows the relationship of the percentage of pain relief (PPR) at 1 month after SCS surgery versus the length of the SCS effect. The *black diamonds* and *gray squares* indicate patients with a continuing SCS effect over 12 months (long-term effect) and patients with a SCS effect less than 12 months (no long-term effect), respectively. The *dotted line* indicates the cut-off value line for the PPR at 1 month after surgery. This line divides the long-term effect from the no long-term effect. The cut-off value is 50%, with a sensitivity of 100% and a specificity of 75%.](nmc-58-422-g001){#F1}

![Comparison between excellent and good groups of MCS/SCS. Line graphs show the changes of the average VAS scores and the standard deviation of the excellent and good groups for MCS (a) and SCS (b). The *black* and *gray lines* indicate the excellent and good groups, respectively. There were no statistically significant differences between the VAS scores at baseline for both the MCS and SCS. After 6 months, however, the VAS scores of the good groups significantly increased as compared to the excellent groups (\**P* \< 0.05, \*\**P* \< 0.001).](nmc-58-422-g002){#F2}

###### 

Demographics and outcomes of patients undergoing motor cortex stimulation

  No   Age   Sex   Pain         Sensory disturbance          Motor weakness   Trial success   Long-term effect   Follow-up (m)   VAS                                              
  ---- ----- ----- ------------ ---------------------------- ---------------- --------------- ------------------ --------------- ----- ---- ----- ----- ----- ---- ---- ---- ---- ----
  1    31    M     Spine        SCI                          1                Rt              UE                 \+              \+    --   Yes   Yes   135   10   2    7    7    7
  2    46    M     Peripheral   Brachial plexus avulsion     2                Rt              UE                 \+              −     ms   No    NA    --    10   --   --   --   --
  3    59    M     Brain        CPSP (hemo)                  2                Rt              UE, LE             \+              −     mi   Yes   No    12    10   5    7    7    --
  4    70    M     Brain        CPSP (hemo)                  5                Rt              UE, LE             \+              −     mi   Yes   No    14    10   7    7    7    8
  5    61    F     Brain        CPSP (hemo)                  3                Rt              LE                 \+              −     mi   Yes   No    6     8    7    8    --   --
  6    52    M     Brain        CPSP (inf)                   6                Rt              UE, LE             \+              \+    mi   Yes   Yes   150   7    2    2    2    2
  7    57    F     Brain        CPSP (hemo)                  4                Lt              UE, LE             \+              \+    mi   Yes   Yes   129   10   3    3    3    3
  8    58    M     Brain        CPSP (inf)                   2                Lt              UE, LE             \+              \+    ms   No    NA    --    9    --   --   --   --
  9    56    F     Brain        CPSP (inf)                   10               Lt              UE, LE             \+              −     --   Yes   Yes   126   10   2    2    3    3
  10   45    F     Spine        SCI                          5                Bil             UE                 \+              −     ms   Yes   Yes   125   9    4    4    6    6
  11   55    M     Brain        CPSP (hemo)                  1                Rt              UE, LE             \+              \+    mi   No    NA    --    6    --   --   --   --
  12   33    M     Brain        Multiple sclerosis           3                Lt              face               \+              −     --   Yes   Yes   72    10   4    4    4    4
  13   69    M     Brain        CPSP (hemo)                  3                Rt              UE, LE             \+              −     mi   No    NA    --    9    --   --   --   --
  14   82    F     Peripheral   Damage of trigeminal nerve   2                Rt              Face               \+              \+    --   Yes   Yes   26    10   3    3    5    5
  15   67    F     Peripheral   Damage of trigeminal nerve   4                Rt              face               \+              \+    --   Yes   Yes   80    8    4    5    4    4

Allo: allodynia, Bil: bilateral, CPSP: central poststroke pain, F: female, hemo: hemorrhage, Hypo: hypoesthesia, inf: infarction, Last: last follow up, Lat: laterality, LE: lower extremity, Lt: left, m: month, M: male, mi: minimal, ms: moderate/severe, NA: not applicable, Preop: preoperative, Rt: right, SCI: spinal cord injury, UE: upper extremity, VAS: visual analog scale.

###### 

Demographics and outcomes of patients undergoing spinal cord stimulation

  No   Age   Sex   Pain         Sensory disturbance   Motor weakness   SCS location   SCS lead   Trial success   Long-term effect   Follow-up (m)   VAS                                                   
  ---- ----- ----- ------------ --------------------- ---------------- -------------- ---------- --------------- ------------------ --------------- ------- -------- ----- ----- ---- ---- ---- ---- ---- ----
  1    82    F     Peripheral   other                 1                Bil            LE         −               \+                 −               L       4c × 2   Yes   Yes   27   10   7    5    5    5
  2    65    F     Peripheral   FBSS                  4                Lt             LE, L      −               \+                 ms              Th      4c × 2   Yes   Yes   18   10   3    6    6    7
  3    75    F     Brain        CPSP (hemo)           6                Rt             UE, LE     \+              −                  ms              Th      4c × 1   Yes   No    2    10   6    --   --   --
  4    78    M     Peripheral   FBSS                  9                Bil            L          −               −                  −               Th      4c × 2   Yes   Yes   48   10   6    5    5    2
  5    67    M     Brain        CPSP (hemo)           14               Rt             UE, LE     \+              \+                 ms              C       8c × 2   No    NA    --   8    --   --   --   --
  6    38    M     Brain        Contusion             5                Lt             UE, LE     \+              −                  --              C, Th   4c × 4   Yes   Yes   85   10   1    1    2    2
  7    69    M     Brain        CPSP (hemo)           9                Rt             UE, LE     \+              \+                 --              Th      8c × 2   Yes   No    6    8    5    8    --   --
  8    50    M     Brain        CPSP (hemo)           5                Lt             LE         \+              \+                 mi              L       8c × 2   Yes   Yes   81   8    1    1    1    1
  9    64    M     Brain        CPSP (hemo)           1                Bil            LE         \+              −                  mi              Th      8c × 2   Yes   No    5    7    5    --   --   --
  10   63    F     Brain        CPSP (inf)            7                Lt             LE, L      \+              \+                 ms              Th      8c × 2   Yes   Yes   83   6    1    2    2    2
  11   59    F     Brain        CPSP (hemo)           1                Lt             UE, LE     −               −                  mi              Th      8c × 2   Yes   Yes   80   7    1    1    1    1
  12   70    F     Brain        CPSP (hemo)           5                Lt             UE, LE     −               −                  --              Th      8c × 2   Yes   Yes   81   9    1    2    6    6
  13   68    M     Brain        CPSP (hemo)           6                Lt             UE, LE     \+              \+                 mi              Th      8c × 1   No    NA    --   7    --   --   --   --
  14   69    F     Spine        SCI                   18               Bil            LE         \+              −                  ms              Th      8c × 1   Yes   Yes   65   8    3    3    3    3
  15   75    F     Srain        CPSP (hemo)           1                Rt             LE         −               \+                 mi              Th      8c × 1   No    NA    --   8    --   --   --   --
  16   51    M     Peripheral   FBSS                  2                Rt             UE         \+              \+                 --              C       8c × 2   Yes   No    12   10   5    8    8    --
  17   77    F     Peripheral   CRPS type1            6                Rt             UE         \+              −                  --              C       8c × 2   Yes   Yes   63   10   1    1    1    1
  18   66    M     Peripheral   FBSS                  4                Bil            L          \+              −                  ms              Th      8c × 2   Yes   No    3    6    3    --   --   --
  19   75    M     Brain        CPSP (hemo)           3                Lt             UE, LE     \+              \+                 mi              Th      8c × 2   No    NA    --   6    --   --   --   --
  20   56    M     Brain        CPSP (hemo)           2                Rt             UE, LE     \+              \+                 --              C, Th   4c × 4   Yes   Yes   36   6    1    1    1    1
  21   64    M     Spine        SCI                   4                Bil            UE         \+              −                  --              C       8c × 2   Yes   Yes   43   8    2    3    3    4
  22   41    M     Spine        SCI                   3                Bil            L          \+              −                  --              Th      8c × 1   Yes   Yes   39   5    2    2    2    2
  23   77    M     Peripheral   FBSS                  1                Lt             LE         −               \+                 ms              Th      8c × 2   Yes   Yes   30   10   7    7    7    7
  24   72    M     Spine        SCI                   1                Bil            UE         −               \+                 --              C       8c × 2   Yes   No    4    8    7    7    --   --
  25   40    M     Peripheral   PNP                   2                Bil            UE         −               \+                 --              C       8c × 2   Yes   Yes   30   7    1    1    1    1
  26   76    F     Peripheral   FBSS                  2                Bil            LE, L      −               \+                 --              Th      8c × 2   Yes   Yes   23   6    1    1    1    1
  27   47    F     Brain        CPSP (inf)            2                Lt             LE         \+              \+                 --              Th      8c × 2   Yes   Yes   18   8    4    5    5    5
  28   62    M     Brain        CPSP (inf)            1                Lt             UE, LE     −               \+                 ms              Th      8c × 2   Yes   Yes   21   10   4    7    7    7
  29   60    F     Peripheral   PNP                   6                Bil            LE         −               −                  --              Th      8c × 2   No    NA    --   10   --   --   --   --
  30   46    F     Peripheral   PNP                   1                Rt             LE, L      −               −                  --              Th      8c × 2   No    NA    --   10   --   --   --   --
  31   44    F     Peripheral   FBSS                  3                Lt             LE         \+              −                  --              Th      8c × 2   Yes   Yes   12   9    6    6    6    6
  32   57    M     Brain        CPSP (hemo)           2                Lt             UE, LE     \+              \+                 --              C, Th   8c × 2   No    NA    --   10   --   --   --   --
  33   76    F     Brain        CPSP (hemo)           4                Lt             UE, LE     \+              \+                 --              C, Th   8c × 2   No    NA    --   9    --   --   --   --
  34   67    F     Peripheral   Other                 6                Bil            Other      −               \+                 --              Th      8c × 2   Yes   Yes   12   8    3    1    1    1
  35   73    F     Brain        CPSP (hemo)           6                Lt             UE, LE     \+              \+                 ms              Th      8c × 2   Yes   No    1    9    8    --   --   --

Allo: allodynia, Bil: bilateral, C: cervical, CPSP: central poststroke pain, CRPS: complex regional pain syndrome, F: female, FBSS: failed back surgery syndrome, hemo: hemorrhage, Hypo: hypoesthesia, inf: infarction, L: lumbar, Last: last follow up, Lat: laterality, LE: lower extremity, Lt: left, m: month, M: male, mi: minimal, ms: moderate/severe, NA: not applicable, PNP: peripheral neuropathy, Preop: reoperative, Rt: right, SCI: spinal cord injury, Th: thoracic, UE: upper extremity, VAS: visual analog scale, 4c: four-contact electrode, 8c: eight-contact electrode.

###### 

Motor cortex and spinal cord stimulation outcomes and details

                                    **MCS (*n* = 15)**   **SCS (*n* = 35)**
  --------------------------------- -------------------- --------------------
  Location of lesion                                     
    Total trial success (rate)      11/15 (73.3%)        27/35 (77.1%)
      Brain                         7/9 (77.8%)          12/18 (66.7%)
      Spine                         2/2 (100%)           4/4 (100%)
      Peripheral                    2/3 (66.7%)          11/13 (84.6%)
    Total long-term effect (rate)   8/15 (53.3%)         20/35 (57.1%)
      Brain                         4/9 (44.4%)          8/18 (44.4%)
      Spine                         2/2 (100%)           3/4 (75%)
      Peripheral                    2/3 (66.7%)          9/13 (69.2%)
  Causes of pain                                         
    Trial success (rate)                                 
      CPSP                          6/9 (66.7%)          11/17 (64.7%)
      SCI pain                      2/2 (100%)           4/4 (100%)
      FBSS                          --                   7/7 (100%)
      CRPS type I                   --                   1/1 (100%)
    Long-term effect (rate)                              
      CPSP                          3/9 (33.3%)          7/17 (41.2%)
      SCI pain                      2/2 (100%)           3/4 (75%)
      FBSS                          --                   5/7 (71.4%)
      CRPS type I                   --                   1/1 (100%)

CPSP: central poststroke pain, CRPS: complex regional pain syndrome, FBSS: failed back surgery syndrome, MCS: motor cortex stimulation, SCI: spinal cord injury, SCS: spinal cord stimulation.

###### 

Comparison of characteristics among the groups for the long-term effect, no long-term effect, and no trial success for motor cortex stimulation

                                                **Long-term effect**   **No long-term effect**   **No trial success**   ***P*-value**
  --------------------------------------------- ---------------------- ------------------------- ---------------------- ------------------------------------------
  Number                                        8                      3                         4                      
  Age                                           52.9 ± 16.9            63.3 ± 5.9                57.0 ± 9.5             0.5535
  Sex (M/F)                                     3/5                    2/1                       4/0                    0.1133
  Duration of pain (years)                      4.4 ± 2.8              3.3 ± 1.5                 2.0 ± 0.8              0.261
  Location of lesion (Brain/spine/peripheral)   4/2/2                  3/0/0                     3/0/1                  0.6643
  Sensory disturbance                                                                                                   
    Hypoesthesia                                8                      3                         4                      1
    Allodynia                                   5                      0                         2                      0.3082
  Motor weakness (Minimal/moderate + severe)    2/1                    3/0                       2/2                    0.06636
  Site of pain                                                                                                          0.4409
    UE                                          2                      0                         1                      
    LE                                          0                      1                         0                      
    UE + LE                                     3                      2                         3                      
    Face                                        3                      0                         0                      
  Laterality of pain                                                                                                    
    Bilateral/left/right                        1/3/4                  0/0/3                     0/1/3                  0.8657
  VAS                                                                                                                   
    Preop.                                      9.3 ± 1.2              9.3 ± 1.2                 8.5 ± 1.7              0.6182
    1 m                                         3.0 ± 0.9              6.3 ± 1.2                 --                     0.01212[^a^](#TFN5){ref-type="table-fn"}
    6 m                                         3.9 ± 1.8              7.3 ± 0.6                 --                     0.0303[^a^](#TFN5){ref-type="table-fn"}
    12 m                                        4.3 ± 1.7              --                        --                     --
    Last                                        4.3 ± 1.7              --                        --                     --
  PPR (%)                                                                                        --                     
    1 m                                         67.1 ± 11.0            30.8 ± 18.8               --                     --
    6 m                                         57.7 ± 20.1            20.0 ± 17.3               --                     --
    12 m                                        54.3 ± 16.4            --                        --                     --
    Last                                        54.3 ± 16.4            --                        --                     --

F: female, Last: last follow-up, LE: lower extremity, m: month, M: male, PPR: percentage of pain relief, Preop.: preoperative, UE: upper extremity, VAS: visual analog scale,

Statistically significant.

###### 

Comparison of characteristics among the groups for the long-term effect, no long-term effect, and no trial success for spinal cord stimulation

                                                **Long-term effect**   **No long-term effect**   **No trial success**   ***P*-value**
  --------------------------------------------- ---------------------- ------------------------- ---------------------- -------------------------------------------
  Number                                        20                     7                         8                      
  Age                                           61.3 ± 13.9            67.1 ± 8.1                65.5 ± 10.6            0.4835
  Sex (M/F)                                     9/11                   5/2                       4/4                    0.5846
  Duration of pain (yrs)                        4.4 ± 3.9              4.1 ± 3.0                 4.6 ± 4.3              0.9705
  Location of lesion (Brain/spine/peripheral)   8/3/9                  4/1/2                     6/0/2                  0.5604
  Sensory disturbance                                                                                                   
    Hypoesthesia                                10                     6                         5                      0.2618
    Allodynia                                   11                     4                         6                      0.6468
  Motor weakness (Minimal/moderate + severe)    3/5                    2/2                       3/1                    0.6993
  Site of pain                                                                                                          0.7235
    UE                                          3                      2                         0                      
    LE                                          6                      1                         2                      
    UE + LE                                     5                      3                         5                      
    Lumbar                                      2                      1                         0                      
    Lumbar + LE                                 3                      0                         1                      
    Other                                       1                      0                         0                      
  Laterality of pain                                                                                                    
    Bilateral/left/right                        8/10/2                 3/1/3                     1/3/4                  0.09163
  VAS                                                                                                                   
    Preop.                                      8.3 ± 1.7              8.3 ± 1.5                 8.5 ± 0.5              0.9309
    1 m                                         2.8 ± 2.2              5.6 ± 1.6                 --                     0.00637[^a^](#TFN7){ref-type="table-fn"}
    6 m                                         3.1 ± 2.3              7.6 ± 0.6                 --                     0.001694[^a^](#TFN7){ref-type="table-fn"}
    12 m                                        3.5 ± 2.6              8                         --                     --
    Last                                        3.3 ± 2.4              --                        --                     --
  PPR (%)                                                                                                               
    1 m                                         67.6 ± 21.2            32.8 ± 16.2               --                     --
    6 m                                         64.7 ± 22.1            10.8 ± 10.1               --                     --
    12 m                                        60.4 ± 25.4            20                        --                     --
    Last                                        62.3 ± 23.4            --                        --                     --

F: female, Last: last follow-up, LE: lower extremity, m: month, M: male, PPR: percentage of pain relief, Preop.: preoperative, UE: upper extremity, VAS: visual analog scale,

Statistically significant.
